Dor Abelman, BS, on Multiple Myeloma: Can Baseline cfDNA Fragmentomics Identify Patients at Risk of Early Progression?

Posted: Wednesday, June 10, 2026

Dor Abelman, BS, of the University of Toronto, reviews findings which support cfDNA fragmentomics as a practical liquid-biopsy risk biomarker in multiple myeloma and suggest higher signals may proxy aggressive disease with greater tumor shedding and chromatin disorganization (AACR Annual Meeting 2026; Abstract 2597 /16).